INTRODUCTION
Introduced in the 1950s, methotrexate continues to be one of the most widely used systemic immunosuppressive agents in dermatology [1, 2] We present a case of methotrexate toxicity manifesting with cutaneous ulceration and review the literature, highlighting practice points relevant to dermatology.
METHOTREXATE

Uses
Methotrexate is licensed for the treatment of severe psoriasis, psoriatic arthritis, rheumatoid arthritis, and a number of malignancies, including: childhood acute lymphoblastic leukemia, lymphoproliferative disorders, choriocarcinoma, and various solid organ tumors. In addition, methotrexate is an abortifacient used in early and ectopic pregnancy and is used off-license in a host of dermatological conditions including atopic eczema [5, 6] and bullous pemphigoid [1] [16] .
It is postulated that the addition of methotrexate to biologic therapy may allow the maintenance of therapeutic benefit through the reduction of formation of anti-infliximab autoantibodies [11] . While this has not been conclusively demonstrated in dermatology patients [17] , evidence in rheumatology cohorts suggests that addition of immunosuppressive drugs to biologic therapy does reduce the induction of anti-tumor necrosis factor antibodies [17] .
Mechanism of Action
Methotrexate may be administered orally, subcutaneously, or intramuscularly.
Methotrexate is primarily bound to serum albumin and excreted unchanged in the urine [1] . Risk of hepatotoxicity is increased by concurrent alcohol consumption, obesity, hepatitis, diabetes mellitus, and cumulative doses of more than 3 g of methotrexate [32] . Monitoring for liver toxicity may include regular serum liver function testing, serial measurement of procollagen III peptide, liver biopsy, and/or transient elastography scanning [33] , although robust evidence to support the utility of one or more potential biomarkers of liver toxicity is lacking.
A key cause of toxicity is concurrent treatment with interacting agents that decrease protein binding or reduce renal clearance. Some interactions (e.g., for
proton-pump inhibitors) have been reported mainly during high-dose methotrexate regimens [34] while others [such as trimethoprim, non-steroidal anti-inflammatory drugs (NSAIDs), and salicylates] have also been reported in patients on low-dose methotrexate [35] . Patients and physicians should be alert to possible interactions and regularly review additional medication use.
A number of cutaneous adverse events have also been described, including: mucositis [36] , erythema multiforme [37] , Stevens-Johnson syndrome [38] , toxic epidermal necrolysis [39, 40] , photosensitivity [41] , 'recall reactions' of previous photodermatoses [42] , exfoliative dermatitis [43, 44] , and ulceration/skin necrosis [4] . Of these, mucositis and photosensitivity are usually dose-related and more commonly associated with high-dose regimens used in chemotherapy than in low-dose therapy used in dermatology [36, 42] . On attendance the patient was systemically well and afebrile. Clinically she had oral erosions to the buccal mucosa ( Fig. 1) and large, painful, inflamed, and ulcerated psoriatic plaques each with a prominent tender erythematous weepy inflamed edge (Fig. 2) .
Routine bloods demonstrated a low platelet count of 109 (normal range 150-400 9 10 9 /L).
Renal function was normal and methotrexate level measured at the time of admission was undetectable.
Skin biopsy taken from the edge of an inflamed plaque on the trunk demonstrated attenuation of relatively atrophic epidermis with overlying parakeratotic scale and apoptotic keratinocytes (Figs. 3, 4) .
A diagnosis of methotrexate toxicity was made; the drug was discontinued and topical therapy commenced. Symptoms and signs resolved within 2 weeks following withdrawal of methotrexate. Treatment was reintroduced at a lower dose of 10 mg of methotrexate weekly with concomitant folic acid supplementation (5 mg daily for 6 days of the week, omitted on day of methotrexate dose) with no adverse effects.
Informed consent was obtained from the patient for being included in the study and for publication of the images.
DISCUSSION
Methotrexate-Induced Cutaneous Ulceration
Ulceration of the skin was well-recognized with aminopterin [46] , the precursor to methotrexate, and was also reported shortly after the introduction of the methotrexate as a treatment for psoriasis [47] . It has been at the onset of treatment [48] , during long-term Histology from skin biopsy taken from the edge of an inflamed plaque on the trunk methotrexate therapy [49] , and as a presenting feature of accidental overdose [50] .
The exact incidence of methotrexate-induced skin ulceration is difficult to assess, but appears to be rare. Roenigk et al. [47] 58] . Non-specific ulceration may also be present [58] .
As with other methotrexate toxicity, skin ulceration has been described in the context of an adverse drug interaction when new medications are added to an existing methotrexate regimen [62] . Examples include; trimethoprim, amiodarone [63] , furosemide [63] , penicillin [63] , and NSAIDs [51] .
Additional risk factors include renal impairment and diabetes mellitus [50] .
Treatment of Methotrexate Toxicity
Folate supplementation during treatment has been shown to reduce methotrexate toxicity [31] and improve compliance with treatment. There is considerable variation in the prescription of folic acid, however, a minimum of 5 mg weekly (to be taken the day after methotrexate therapy) is recommended for UK practice [3] .
In cases of ulceration, withdrawal of methotrexate supported by skin-directed therapy usually leads to rapid improvement in ulceration with many patients showing signs of healing within a few days; however, in isolated cases ulceration persists for years [4] . [50, 55] . This treatment should be administered as soon as possible after exposure to methotrexate in 20 mg doses (or 10 mg/m 2 )
intravenously or intramuscularly, every 6 h until serum methotrexate concentration falls below 10 -8 M (assessed every 12-24 h) or until the total dose of folinic acid is at least equal to the dose of methotrexate [32] .
In patients with impaired renal function receiving high-dose methotrexate for cancer therapy who develop toxicity, glucarpidase has been used to hydrolyze methotrexate aiding clearance [64] . Glucarpidase is a recombinant bacterial enzyme and received Food and Drug
Administration approval in 2012 [65] . It also has some limited application in cases of intrathecal methotrexate toxicity [65] . As yet there are no reports of this agent used within the dermatology population, however, there might be applications in cases of acute overdose. 
CONCLUSION
